FDA approves Flexion's Zilretta for OA knee pain

Flexion Therapeutics Inc. (NASDAQ:FLXN) added $2.81 (10%) to $21.93 on Friday after FDA approved its Zilretta triamcinolone acetonide to treat osteoarthritis knee pain.

Flexion plans to launch the product this month at a price of $570 per dose. The company said Zilretta is designed to deliver pain relief over 12 weeks in patients with moderate to severe OA knee pain...